Belite Bio shares slide as FDA extends tinlarebant review by three months
In short
Belite Bio shares fell following an announcement that the U.S. Food and Drug Administration has extended its review of the drug tinlarebant. The regulatory agency lengthened the review period by three months.
Key points
- Belite Bio shares fell following an announcement that the U.S.: Belite Bio shares fell following an announcement that the U.S.
- Food and Drug Administration has extended its review of the drug tinlarebant.: Food and Drug Administration has extended its review of the drug tinlarebant.
- The regulatory agency lengthened the review period by three months.: The regulatory agency lengthened the review period by three months.